Information Provided By: 
Fly News Breaks for January 24, 2018
MYL
Jan 24, 2018 | 05:18 EDT
Deutsche Bank analyst Gregg Gilbert raise his price target for Mylan to $50 from $48 saying biosimilars could be an important driver of longer-term growth. Mylan has one of the largest biosimilar pipelines in the industry and could launch its first biosimilar in the U.S., pegfilgrastim, this year, Gilbert tells investors in a research note. He keeps a Buy rating on the shares.
News For MYL From the Last 2 Days
There are no results for your query MYL
